BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal

benzinga.com/m-a/25/06/45907865/biontech-mrna-cancer-portfolio-curevac-all-stock-deal

BioNTech SE (NASDAQ:BNTX) on Thursday agreed to acquire CureVac N.V. (NASDAQ:CVAC) in an all-stock transaction.
According to the agreement, shareholders can exchange CureVac shares for around $5.46 in BioNTech ADSs. This equates, roughly, to an equity value of $1.25 billion.
The…

This story appeared on benzinga.com, 2025-06-12 15:07:51.
The Entire Business World on a Single Page. Free to Use →